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Platelet-Derived Growth Factor (PDGF)
Gene Delivery for Application in
Periodontal Tissue Engineering
William V. Giannobile,* Caroline S. Lee,* Matthew P. Tomala,* Kristina M. Tejeda,* and Zhimin Zhu†
Background: A challenge in the reconstruction of periodon-
tal structures is the targeted delivery of growth-promoting mol-
ecules to the tooth root surface. Polypeptide growth factors such
as platelet-derived growth factor (PDGF) stimulate both cemen-
togenesis and osteogenesis. Recent advances in gene therapy
offer the advantage of delivering recombinant proteins to tis-
sues for extended periods of time in vivo.
Methods: Recombinant adenoviral vectors encoding for the
PDGF-A gene were constructed to allow delivery of PDGF trans-
genes to cells. The recombinant adenoviruses were assembled
using the viral backbone of Ad2/CMV/EGFP and replacing GFP
(reporter gene encoding green fluorescent protein driven by the
cytomegalovirus promoter [CMV] within adenovirus type 2) with
the PDGF-A gene. Root lining cells (cloned cementoblasts) were
transduced with Ad2/PDGF-A and evaluated for gene expres-
sion, DNA synthesis, and cell proliferation. PDGF-inducible
genes, c-myc and osteopontin, were also evaluated following
gene delivery of Ad2/PDGF-A.
Results: The results revealed high level transduction of
cementoblasts by gene transfer for 7 days as evidenced by flow
cytometry and Northern blotting. Cementoblast DNA synthesis
and subsequent proliferation were stimulated by Ad2/PDGF-A
at levels equal to or greater than continuous rhPDGF-AA appli-
cation. Strong message for the PDGF-A gene and protein as
evidenced by Northern blotting and immunocytochemistry was
noted. Furthermore, the potent induction of c-myc and osteo-
pontin mRNA was found after PDGF gene delivery to cemento-
blasts.
Conclusions: These findings demonstrate that gene delivery
of platelet-derived growth factor stimulates cementoblast activ-
ity that is sustained above that of rhPDGF-AA application. The
use of gene therapy as a mode of growth factor delivery offers
a novel approach to periodontal tissue engineering. J Periodontol
2001;72:815-823.
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The success of tissue engineeringrelies on the large-scale purifica-tion and production of signaling
molecules, as well as methods to deliver
these factors to their targets.1 One prob-
lem with current growth factor delivery
to periodontal wounds is the extremely
short half-life of the factors. Topically-
administered growth factors remain in the
periodontal defect for a limited duration,
presumably due to proteolytic break-
down, receptor-mediated endocytosis,
and the solubility of the delivery vehicle.2
Therefore, the use of DNA delivery sys-
tems may serve as an alternative method
of targeting proteins to periodontal
wounds, since existing protein delivery
systems provide such a transient action
of the administered growth factor. Gene
therapy has been applied to several dis-
eases that display tissue deficiencies
(e.g., skin and bone injury).3,4 Therefore,
the use of gene therapy to promote repair
and regeneration has become an active
area of research.5 In the context of wound
repair, a transient expression of a puta-
tive transgene may be advantageous to
restore the tissue defect. Examples of
methods of gene delivery for short-term
expression of genes include adenovirus
and DNA-lipid complexes.6 Since the reg-
ulation of wound repair occurs in a con-
trolled fashion over a defined period of
time, the use of gene therapeutics in
chronic wounds (e.g., periodontal dis-
ease) may stimulate an elevated and sus-
tained production of growth factors to
promote tissue regeneration.7
Recombinant adenoviral expression in
vivo has been demonstrated to extend
for up to 35 days depending on the tis-
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sue transduced and route of administration.8
Adenovirus has a transient expression pat-
tern due to ability of the virus to remain extra-
chromosomal (i.e., episomal) as a noninte-
grating virus. The total level of recombinant
virus in vivo decreases over time depending
on the lifespan of the cells infected and the
attenuation of the virus expression by host
immunologic mechanisms.9
Platelet-derived growth factor (PDGF) was
studied for gene delivery given its consistent
results in stimulating periodontal tissue regen-
eration.10-12 PDGF elicits its biologic effects
by binding to cell-surface receptors (PDGF-
αR and -βR) possessing intrinsic tyrosine
kinase activity which signal the cell to
undergo mitosis, chemotaxis or matrix syn-
thesis.13 Our strategy was to insert the PDGF
gene into a transiently expressing viral vec-
tor (i.e., adenovirus) for gene targeting to quiescent and
replicating cells. By using a “longer-term” delivery of
PDGF we can use the extended expression pattern of
PDGF receptors following tissue injury to our advan-
tage.14,15 Several groups have delivered growth factor
genes to healing skin,16,17 bone,4,18 and periodontal19
wounds using plasmid DNA. The use of biodegradable
polymers to deliver PDGF DNA offers promise in tis-
sue repair.20 Other investigators have delivered bone
morphogenetic protein (BMP) genes by adenovirus to
orthotopic wounds by ex vivo approaches with impres-
sive results.21-23 Eriksson et al. have developed unique
methods of transducing wounds by the in vivo
microseeding technique3,24 which we have adapted to
periodontal wounds.19 Furthermore, with the recent
characterization of root lining cells that possess phe-
notypic characteristics similar to cementoblasts, we
are now able to investigate the delivery of PDGF trans-
genes to cementoblasts.25
The objective of this study was to determine the
ability of a recombinant adenovirus encoding PDGF-A
to transduce and modulate the activity of cemento-
blasts. The investigation of growth factor gene ther-
apy may provide a better understanding of cemento-
genesis and periodontal tissue regeneration, which
could prove useful in future therapeutics.
MATERIALS AND METHODS
Construction of Recombinant Adenoviruses
We have previously described the construction of ade-
noviruses encoding PDGF genes which is shown in
diagrammatic form in Figure 1.26 In brief, the full-
length murine PDGF-A cDNA (gift of Dr. Charles D.
Stiles, Dana-Farber/Harvard Cancer Center) was sub-
cloned into a shuttle plasmid (pAD2/CMV/SVIX),‡
under the control of the cytomegalovirus (CMV) pro-
moter. The viral backbone DNA Ad2/EGFP (aden-
ovirus encoding the gene for green fluorescent protein
[GFP]) was precut with PshAI and the shuttle plasmid
containing either PDGF-A or PDGF-1308 cDNA was
linearized with XbaI. The linearized shuttle plasmid
and viral backbone DNA were co-transfected into 293
packaging cells (human embryonic kidney cells trans-
formed with wild-type adenovirus) using calcium phos-
phate transfection. Recombination between the shut-
tle plasmid and the GFP viral backbone resulted in
substitution of the GFP cDNA with PDGF-A cDNA
(Fig. 1). At 8 to 10 days post-transfection, recombi-
nant viral plaques were readily identified under
inverted fluorescent microscopy by lack of fluores-
cence. Recombinant plaques were plaque purified and
expanded for large-scale purification of the viral stocks
using ultracentrifugation with a cesium chloride gra-
dient. The cesium chloride-containing viral stocks were
desalted and viral stocks were stored at −80°C. Titers
of the virus stocks were determined on 293 cells by
plaque formation assay and expressed as the number
of plaque forming units (pfu) per ml.
Cell Culture
The cementoblast cell cultures used in these experi-
ments are described in detail in several reports by
Somerman and colleagues.27-30 Briefly, cells were
obtained from the root surface of first mandibular
molars of OC-TAg transgenic mice. These mice con-
tain the SV40 large T-antigen (TAg) under control of
the osteocalcin (OC) promoter. Therefore, only cells
that express OC also express TAg and are immortal-
ized in vitro. Based on results of prior in situ studies,
OC is expressed by cementoblasts during root devel-
opment, but not by cells within the periodontal liga-
ment (PDL). Consequently, when cell populations are
‡ Genzyme Corporation, Cambridge, MA.
Figure 1.
Schematic representation of the constructs used to synthesize the replication-deficient
recombinant adenovirus containing the full-length murine PDGF-A cDNA. Note 5
CMV promoter, adenoviral genes, which include E2, E3, and E4, and flanking ITR.
Recombinant adenoviruses are generated after homologous recombination between
pAd2/CMV/PDGF-A and linearized,Ad2/GFP genome as outlined in the materials and
methods. ITR: inverted terminal repeat; CMV: cytomegalovirus promoter.
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isolated from developing molars using enzyme diges-
tion, only cementoblasts (not PDL cells) are immor-
talized and thus will survive in culture. The resulting
immortalized cementoblast population (OC/CM)
express bone sialoprotein (BSP), osteopontin (OPN),
and OC, markers selective to cells lining the root sur-
face. These cells also promote mineral nodule for-
mation both in vitro and in vivo.25,31 The cells uti-
lized were from OC/CM clone 30, which were tested
to confirm the expression of osteocalcin and bone
sialoprotein by Northern blotting prior to utilization in
experiments.
Gene Transfer to Cementoblasts
Cementoblasts were plated at subconfluence (80%)
in Dulbecco’s modified Eagle medium (DMEM) sup-
plemented with 10% bovine calf serum (BCS) and
antibiotics. Cells were then transduced with recombi-
nant adenoviruses (Ad2/GFP or Ad2/PDGF-A) at a
multiplicity of infection (MOI) = 100 (i.e., one MOI unit
is that amount of virus required to form a plaque on
a standard virus plaque forming assay; therefore, a
MOI = 100 would equal 100 plaque forming units for
each cell). After 4 of 5 hours of shaking, the medium
was replenished with fresh 10% BCS and the cells
maintained and evaluated for subsequent experiments
(below). Depending on the experiment, cells were
transferred to 5% platelet-poor plasma to negate the
effects of PDGF and other growth factors found in
bovine calf serum.
Flow Cytometry
Flow cytometry was performed to determine trans-
duction efficiency of the Ad2/CMV/GFP control vector,
which was used to generate the PDGF-A recombinant
adenovirus, to cementoblasts. The cells were plated
at a seeding density of 1 × 106 cells/dish in 60 mm
culture dishes. Cells received either no treatment or
exposure to an ascending range of Ad2/GFP (MOI =
0.1 to 100). The cell monolayers were harvested at
days 1, 2, 4, and 7 after transduction. Single cell sus-
pensions were collected and assessed by cell sorting
at the University of Michigan Flow Cytometry Facility.
Fluorescence intensity was plotted against total cell
number to calculate the proportion of cells exhibiting
fluorescence (i.e., percentage of cells expressing GFP).
Northern Blotting
Cementoblasts were plated at a density of 4 × 105
cells/well in 6 well plates. After 24 hours the cells were
transduced with either Ad2/PDGF-A or Ad2/GFP (at
MOI = 100) for 4 to 5 hours. After specified timepoints,
total RNA was isolated from the cells and quantified
by spectrophotometry as previously described.32 Three
µg of total RNA was electrophoresed on 6% formalde-
hyde-1.2% agarose gels, transferred to nylon mem-
branes§ and immobilized by UV crosslinking.§ Mem-
branes were hybridized with the murine PDGF-A cDNA
probe (gift of Dr. Charles D. Stiles, Dana-Farber/Har-
vard Cancer Center), murine osteopontin cDNA probe
(gift of Dr. Marian Young, NIH/NIDCR), or murine c-
myc cDNA (gift of Dr. Craig Logsdon, University of
Michigan) and labeled using a horseradish peroxidase
chemiluminescence technique. Blots were exposed to
autoradiographic film for 20 minutes to 24 hours. Rel-
ative loading of wells was evaluated by ethidium bro-
mide staining of the original agarose gel or hybridiza-
tion of blots with 18S rRNA.33 Transduction efficiency
of Ad2/PDGF-A gene delivery was compared at 24
hours and 7 days after gene transfer to evaluate pro-
longed gene expression. The induction of the imme-
diate-early gene c-myc was assessed at timepoints
ranging from 30 minutes to 48 hours. The induction
of osteopontin gene expression was determined at 24
hours and 48 hours.
Immunohistochemistry
Cementoblasts were plated at a density of 2.0 × 104
cells/well in 4-well RS-coated chamber slides.¶ After
24 hours the medium was changed to DMEM supple-
mented with 5% platelet-poor plasma. The cells were
subsequently transduced with either Ad2/GFP (MOI =
100), or Ad2/PDGF-A (MOI = 100). After 24 hours, the
cells were fixed with 2% paraformaldehyde, perme-
abilized with 0.5% IGEPAL,# and blocked with 2% nor-
mal goat serum. Following treatment with primary anti-
body (150 dilution) specific for PDGF-AA,** the cells
were processed for peroxidase staining using a com-
mercial avidin-biotin complex method kit†† and VIP
substrate.††
Alkaline Phosphatase Activity
OC-CM cells were plated at a density of 1 × 105
cells/well in 24-well plates containing in 10% BCS.
After 12 hours, the medium was changed to 5% platelet
poor plasma. Twelve hours later, cementoblasts were
treated with 20 ng/ml of rhPDGF-AA or transduced
with either Ad2/GFP or Ad2/PDGF-A at MOI = 100.
Alkaline phosphatase activity was assessed 24 hours
following treatment. Cells were evaluated for the abil-
ity to convert p-nitrophenylphosphate to p-nitrophenol
as described previously.34 Monolayers of cells were
released from tissue culture dishes and aliquots of
100,000 cells were counted. The cells were washed
and suspended in 1 ml of 10 mM magnesium sulfate
in saline to activate the enzyme, pelleted, and sub-
jected to the addition of 0.5 ml of alkaline phosphatase
817
§ Strategene, Inc., LaJolla, CA.
 Amersham Life Science, Bucks, UK.
¶ Lab-Tek, Nagle Nunc International, Naperville, IL.
# Sigma Chemical Co., St. Louis, MO.
** Santa Cruz Biotechnology, Santa Cruz, CA.
†† Vector Laboratories, Burlingame, CA.
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substrate incubated for 5 minutes
at 37°C. The reaction was stopped
with 10 ml of 0.05 N NaOH. The
absorbance of the samples was
determined at a wavelength of 400
nm using a spectrophotometer
and compared with a standard
curve generated from prepared
standards. Triplicate wells were
evaluated in 3 separate experi-
ments.
DNA Synthesis Assay
Mitogenic activity due to adenovi-
ral delivery was evaluated as pre-
viously described.35 Cemento-
blasts were plated at a seeding
density of 5,000 cells/well in 96-
well plates for 5 days. Cells were
then washed 3 times with PBS and
stimulated in serum-free medium
with either negative control
(Ad2/GFP MOI = 100); positive
control (10% BCS); rhPDGF-AA‡‡
(at 20 ng/ml); or Ad2/PDGF-A
(MOIs 1-100) for a period of 24
hours. One µCi of [3H]thymidine
(NEN/)/§§well (5 µCi/ml) was
added to the cells during the last
6 hours of incubation. Each well
was fixed with ice-cold tri-
chloroacetic acid (TCA) for 20
minutes. The wells were then
washed 3 times with TCA. Next, 0.25 N NaOH (37°C)
was added for 15 to 30 minutes followed by neutral-
ization by 0.75 N HCl. The contents from each well
were transferred to scintillation vials for measurement
of [3H]thymidine uptake. Tritium levels were measured
on a liquid scintillation counter. The results were
expressed as CPM per 5 wells of 3 separate experi-
ments.
Cell Proliferation
Cementoblasts were plated in 24-well plates at a den-
sity of 2.5 × 104 cells/well in 10% BCS. After a period
of 12 hours to allow cell attachment, the cells were
treated with either 20 ng/ml rhPDGF-AA (in 5% platelet
poor plasma), Ad2/GFP (MOI = 100) or Ad2/PDGF-
A (MOI = 100). After viral infection the medium was
changed to 5% platelet poor plasma to avoid poten-
tial neutralizing antibodies to adenovirus found in the
human-derived platelet poor plasma. The medium was
changed every other day and cells were harvested at
days 1, 2, 4, and 7 after treatment. Cell counts were
made using a hemocytometer on triplicate cell culture
wells.
Statistical Analyses
An analysis of variance with the Bonferroni-Dunn Mul-
tiple comparison procedure was performed to evalu-
ate DNA synthesis and proliferation comparing treat-
ments with corresponding controls. An alpha level of
0.05 was used to determine statistical differences
between groups.
RESULTS
This study demonstrates the effective transduction of
cementoblasts by Ad2/GFP and Ad2/PDGF-A recom-
binant adenoviruses with strong effects on the stimu-
lation of DNA synthesis, cell proliferation and gene
expression.
Flow Cytometry
Cementoblast transduction using the control virus Ad2/
GFP demonstrated a dose-dependent effect on GFP
expression (from MOI 0.1 to 100) for up to 7 days fol-
lowing gene delivery. The MOI of 100 was found to be
optimal in achieving nearly 100% transduction of cemen-
toblasts and was used for subsequent experiments. The
818
Figure 2.
Effective, prolonged gene transfer of Ad2/GFP to cementoblasts. Subconfluent cementoblasts were
transduced with Ad2/GFP at an MOI = 100. After 24 hours the cells were subsequently visualized
under phase contrast (left panel; A) and fluorescence microscopy (right panel; A).The cementoblasts
were then subjected to FACS analysis to determine the percentage of cells transduced by the
adenovirus encoding the jellyfish protein green fluorescent protein (GFP) after 1 and 7 days (B).
Note the stability of protein expression in the cells at 1 and 7 days after gene transfer with >90%
of the cells exhibiting fluorescence intensity above threshold (middle and right panels, respectively;
B). Cells that were not transduced by Ad2/GFP fail to fluoresce (left panel; B) The B designation
gives the total cell count on the cell sorter, while the C designation gives the number of cells which
surpassed the fluorescence threshold (i.e., cells producing GFP).
‡‡ Upstate Biotechnology, Inc., Lake Placid, NY.
§§ NEN Life Sciences, Boston, MA.
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percentage of cells exhibiting fluorescence as an indi-
cator of GFP protein expression was maintained at >90%
for the 7-day observation period (Fig. 2). MOI = 100 was
chosen for subsequent gene transfer experiments since
the highest transduction efficiency was shown by this
MOI without altering cell growth (data not shown).
PDGF Gene Expression
Strong expression of the PDGF-A gene was noted fol-
lowing gene transfer of Ad2/PDGF-A to cementoblasts
(Fig. 3). Furthermore, prolonged gene expression of
PDGF-A was also seen at 7 days following gene deliv-
ery. In contrast, no detectable PDGF-A gene expres-
sion was found in Ad2/GFP-transduced cells at any
timepoint.
Immunohistochemistry. Immunocytochemical analy-
sis of cementoblasts transduced with Ad2/PDGF-A
revealed positive staining with the monospecific PDGF-
AA antibody (Fig. 4) within 24 hours of gene transfer.
For comparison, cells transduced with Ad2/GFP failed
to demonstrate measurable levels of PDGF-AA protein.
DNA Synthesis and Alkaline Phosphatase Activity
Assessment of cementoblast mitogenesis was mea-
sured by [3H]thymidine uptake as shown in Table 1.
Ad2/PDGF-A exposure of cementoblasts significantly
stimulated DNA synthesis above that of control virus
(Ad2/GFP). Furthermore, when Ad2/PDGF-A was
compared to 20 ng/ml of rhPDGF-AA, the stimulation
was indistinguishable (P <0.05) at MOI = 100. In con-
trast, PDGF-A gene transfer and rhPDGF-AA applica-
tion significantly downregulated ALP activity within 24
hours of application (Table 1).
Figure 3.
A representative Northern blotting analysis demonstrating dose-
dependent gene expression of PDGF-A by infected cementoblasts 24
hours and 7 days after transduction. Cementoblasts were transduced
with Ad2/GFP or Ad2/PDGF-A at MOI = 100 as described in the
materials and methods. Prolonged gene expression was found 7 days
after PDGF-A gene transfer. 18S is shown to indicate relative loading of
RNA.
Figure 4.
Immunohistochemical detection of PDGF-AA protein by cementoblasts
transduced with Ad2/PDGF-A. Cementoblasts were plated at
subconfluence for 24 hours in DMEM supplemented with 10% BCS.
The medium was changed to DMEM supplemented with 5% platelet-
poor plasma and cells transduced with either Ad2/GFP (A) or
Ad2/PDGF-A (B) at MOI = 100. After 24 hours, the cells were fixed
with 2% paraformaldehyde, permeabilized with 0.5% IGEPAL and
blocked with 2% normal goat serum. Following treatment with primary
antibody specific for PDGF-A, the cells were processed for peroxidase
staining using a commercial avidin-biotin complex method kit and VIP
substrate. Cementoblasts transduced with Ad/PDGF-A display positive
staining consistent with PDGF-AA, while cells exposed to Ad2/GFP
show minimal staining (original magnification ×20; phase contrast).
Table 1.
Regulation of Cementoblast Mitogenesis
and Alkaline Phosphatase Activity (ALP)
by PDGF-A Gene Transfer
Counts per 
Group Minute ± SD (x 103) ALP ± SD (x 10–6)
Ad2/GFP (control) 225.5 ± 22.7 115.9 ± 16.4
rhPDGF-AA 288.7 ± 18.4* 68.1 ± 15.9‡
Ad2/PDGF-A 240.1 ± 14.3* ND§
(MOI = 1)
Ad2/PDGF-A 290.4 ± 19.0* ND
(MOI = 10)
Ad2/PDGF-A 301.5 ± 9.5* 75.2 ± 16.8‡
(MOI = 100)
Ad2/PDGF-A 150.8 ± 20.7† ND
(MOI = 500)
10% Serum 325.8 ± 30.7* 100.8 ± 15.6
* P <0.001 increase compared to Ad2/GFP.
† P <0.001 reduction compared to Ad2/GFP.
‡ P <0.05 reduction compared to Ad2/GFP.
§ not determined.
rhPDGF-AA = 20 ng/ml.
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Cell Proliferation
Since PDGF has been shown to be a strong stimula-
tor of cementoblasts in vitro,36 continuous exposure of
cells to PDGF was compared to PDGF gene transfer
using adenovirus. All cells responded similarly follow-
ing continuous PDGF protein application or by
Ad2/PDGF-A (Fig. 5). A statistically significant
increase in cell number was noted for cementoblasts
following treatment with rhPDGF-AA or Ad2/PDGF-A
at days 4 and 7. Furthermore, cells treated by
Ad2/PDGF-A also showed significant elevations in cell
number at days 4 and 7 above that of continuous
rhPDGF-AA application (P <0.01).
Expression of PDGF-Inducible Genes
Northern blotting was performed to ascertain the induc-
tion of genes expressed following exposure to PDGF.
Figure 6A reveals the induction in the immediate-early
gene c-myc 6 hours following gene transfer of
Ad2/PDGF-A, while minimal basal levels of c-myc
were noted for Ad2/GFP transduced cells. The positive
control lane demonstrates total RNA from carbachol-
stimulated pancreatic acinar cells. In addition, no sig-
nificant differences in c-myc gene expression were
noted for later timepoints up to 48 hours post-gene
transfer. Figure 6B illustrates the potent induction of
osteopontin mRNA following gene delivery of
Ad2/PDGF-A 48 hours after transduction. Gene expres-
sion for OPN was induced within 24 hours (not shown)
and was increased even further at 48 hours (Fig. 6B).
When 50 µg/ml ascorbic acid was added to the
medium, the induction in OPN mRNA was even more
pronounced.
DISCUSSION
These results demonstrate for the first time
the use of growth factor gene delivery to
root lining cells. Our findings show that
PDGF-A gene transfer is stable in vitro and
that genes known to be modulated by PDGF
are induced by Ad2/PDGF-A, and in a pro-
longed fashion.
The data suggest that gene transfer to a
putative cell type that participates in peri-
odontal regeneration (i.e., the cementoblast)
can be effectively transduced at high levels
(>90% of cells) for extended periods of time
in vitro. However, the gene expression pro-
file would likely be decreased in vivo by the
mounting of a cytotoxic T-lymphocyte
response following adenoviral protein release
by Ad2/PDGF-A.37 Furthermore, the risks
of employing this technique in periodontal
wounds, such as viral load, the immune
response, and the fate of the transduced
cells in vivo, will need to be carefully
assessed. Ongoing studies in both ex vivo
and in vivo gene transfer to the periodontium
seek to examine the extent of the above
effects in modulating periodontal wound
healing.
Figure 5.
Proliferation of cementoblasts following PDGF gene transfer.
Cementoblasts were plated at subconfluence in DMEM supplemented
with 10% BCS for 12 hours. At day 0, the medium was changed to
DMEM containing either 5% platelet-poor plasma containing Ad2/GFP
(circles), rhPDGF-AA (triangles), or Ad2/PDGF-A (squares).The cells
were counted at days 1, 2, 4, and 7 after treatment.The experiment
was repeated twice with typical results shown above. Statistically
significant stimulation of cell growth above that of control virus
(Ad2/GFP) and for continuous PDGF-AA application with Ad2/PDGF-A
gene delivery at day 4 and 7. Error bars represent standard deviation.
*P <0.01.
Figure 6.
PDGF gene transfer alters gene expression of immediate-early and osteoblast-
associated genes in cementoblasts. A. Confluent cementoblasts cultured in 5%
platelet-poor plasma were treated with either Ad2/GFP or Ad2/PDGF-A. RNA
harvested from the cells were run on agarose gels, transferred to nylon membranes
and then probed with the murine c-myc probe 6 hours after gene delivery. Note
induction in the immediate-early gene c-myc in Ad2/PDGF-A transduced cells, while
Ad2/GFP transduced cells reveal minimal c-myc gene expression by Northern blot
analysis.The control lane represents RNA harvested from c-myc expressing
pancreatic acinar cells. B. Confluent cementoblasts were plated in the presence (+)
or absence (–) of ascorbic acid (AA) for 48 hours following gene transfer of PDGF.
Northern analysis reveals the potent induction in osteopontin (OPN) mRNA by PDGF
gene transfer with and without AA addition. Human gingival fibroblasts (hGF) failed to
show measurable OPN gene expression, while differentiated MC3T3 E1 osteoblasts
were used as a positive control.The blots were normalized with an 18S probe or
ethidium bromide staining of the gels.
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PDGF has pleiotropic effects on cells derived from
the periodontium including osteoblasts, periodontal lig-
ament cells, and cementoblasts.36,38,39 Topical appli-
cation of PDGF accelerates tissue repair in a multi-
tude of wound model systems such as skin,40 bone,41
and periodontium.12 Despite encouraging results using
recombinant growth factors in many of these clinical
situations, limitations exist with topical protein deliv-
ery such as short half-life, protease inactivation, and
poor bioavailability from the available delivery vehicles.
Therefore, our approach was to develop a methodol-
ogy to optimize growth factor delivery to maximize the
therapeutic efficacy. Using a genetic approach to tis-
sue engineering may provide a means to achieve deliv-
ery of growth factors directly from the target cells to
overcome many of the shortcomings of protein deliv-
ery.42,43
The results of this study establish the stable expres-
sion of the PDGF-A gene as shown by Northern
blotting (Fig. 3); the production of PDGF-AA protein
as identified by immunohistochemistry (Fig. 4); and
that the PDGF-AA released by cementoblasts pos-
sesses biological activity as demonstrated by DNA
synthesis assay and proliferation (Table 1 and Fig.
5). Furthermore, we show that the PDGF-AA deliv-
ered by gene transfer affects cementoblasts in a
manner consistent with its response by protein deliv-
ery (e.g., stimulation of the immediate-early gene
c-myc). The proto-oncogene c-myc is an important
member of the early responsive nuclear oncogene
family that is induced typically within minutes of
growth factor stimulation. In the case of gene trans-
fer, there is a lag in the induction of c-myc due to
the steps of virus entry into the cell followed by
transcription and subsequent translation of PDGF
protein to induce c-myc mRNA. It was interesting to
note that the biological effects are relatively rapid
considering the steps required for viral infection. The
biologic response (i.e., increase in [3H]thymidine
uptake) is equivalent between PDGF-AA protein and
Ad2/PDGF-A gene transfer within 24 hours of gene
delivery, while over time, Ad2/PDGF-A gene trans-
fer results in increased cementoblast cell numbers
above that of rhPDGF-AA application after 4 and 7
days (Fig. 5).
The induction of osteopontin mRNA following PDGF-
A gene transfer further illustrates the consistency of
effects of viral versus protein delivery of PDGF-AA.
Figure 6B shows the potent induction of OPN gene
expression alone and when combined with ascorbic
acid, an important co-factor in extracellular matrix pro-
duction. This result is comparable to the findings of
Saygin et al. who demonstrated an increase in OPN
gene expression following PDGF-BB application to cul-
tured cementoblasts.36 Osteopontin, which has been
identified in multiple connective tissues,44 promotes
adhesion of osteoblasts and osteoclasts and regulates
mineral crystal growth.45
Prolonged PDGF delivery may have differing effects
on the mineralization process. Studies by Graves and
colleagues46,47 have shown that long-term exposure of
osteoblastic cells to PDGF stimulates proliferation,
while decreasing the expression of the osteoblast phe-
notype with subsequent inhibition of mineralization in
vitro. The finding that PDGF gene delivery inhibits ALP
activity is not unexpected since rapidly proliferating
cells by definition are not expressing the differentiated
cell phenotype (Table 1). Therefore, regulation of the
spatial and temporal levels of PDGF gene expression
in vivo is likely to influence the composition of newly
regenerating periodontal tissues.
In conclusion, the present study demonstrates effec-
tive gene transfer of PDGF-A to cementoblasts in vitro.
The transduction of cementoblasts by PDGF-A results
in stimulation of mitogenesis, proliferation, and expres-
sion of PDGF-inducible genes. Current investigations
are seeking to determine the long-term effects of PDGF
gene transfer on cementogenesis in vitro and in vivo.
Future studies plan to elucidate the role of PDGF gene
therapy in the modulation of periodontal tissue regen-
eration in vivo.
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